Literature DB >> 17405767

A clinical rating scale for progressive supranuclear palsy.

Lawrence I Golbe1, Pamela A Ohman-Strickland.   

Abstract

We devised a Progressive Supranuclear Palsy (PSP) Rating Scale comprising 28 items in six categories: daily activities (by history), behaviour, bulbar, ocular motor, limb motor and gait/midline. Scores range from 0 to 100, each item graded 0-2 (six items) or 0-4 (22 items). Inter-rater reliability is good, with intra-class correlation coefficient for the overall scale of 0.86 (95% CI 0.65-0.98). A single examiner applied the PSPRS at every visit for 162 patients. Mean rate of progression was 11.3 (+/-11.0) points per year. Neither onset age nor gender correlated well with rate of progression. Median actuarially corrected survival was 7.3 years. The PSPRS score was a good independent predictor of subsequent survival (P < 0.0001). For example, for patients with scores from 40 to 49, 3-year survival was 41.9% (95% CI 31.0-56.6) but 4-year survival was only 17.9% (95% CI 10.2-31.5). For those patients, likelihood or retaining some gait function was 51.7% (40.0-66.9) at 1 year but only 6.5% (1.8-23.5) at 3 years. We conclude that the PSPRS is a practical measure that is sensitive to disease progression and could be useful as a dependent variable in observational or interventional trials and as an indicator of prognosis in clinical practice.

Entities:  

Mesh:

Year:  2007        PMID: 17405767     DOI: 10.1093/brain/awm032

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  186 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

2.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.

Authors:  Jennifer L Whitwell; Jia Xu; Jay N Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2011-11-13       Impact factor: 4.891

3.  The relationship between clinical and pathological variables in Richardson's syndrome.

Authors:  Emma C Schofield; John R Hodges; Thomas H Bak; John H Xuereb; Glenda M Halliday
Journal:  J Neurol       Date:  2011-08-12       Impact factor: 4.849

4.  Instability of syllable repetition in progressive supranuclear palsy.

Authors:  Sabine Skodda; Wenke Grönheit; Uwe Schlegel
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

5.  POLG and PEO1 (Twinkle) mutations are infrequent in PSP-like atypical parkinsonism: a preliminary screening study.

Authors:  Matthis Synofzik; Julia Schicks; Karin Srulijes; Claudia Schulte; Franziska Schiele; Daniela Berg; Ludger Schöls
Journal:  J Neurol       Date:  2012-05-12       Impact factor: 4.849

6.  Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.

Authors:  Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-22       Impact factor: 6.200

7.  Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.

Authors:  Günter U Höglinger; Jakob Schöpe; Maria Stamelou; Jan Kassubek; Teodoro Del Ser; Adam L Boxer; Stefan Wagenpfeil; Hans-Jürgen Huppertz
Journal:  Mov Disord       Date:  2017-04-24       Impact factor: 10.338

8.  Intrinsic connectivity network disruption in progressive supranuclear palsy.

Authors:  Raquel C Gardner; Adam L Boxer; Andrew Trujillo; Jacob B Mirsky; Christine C Guo; Efstathios D Gennatas; Hilary W Heuer; Eric Fine; Juan Zhou; Joel H Kramer; Bruce L Miller; William W Seeley
Journal:  Ann Neurol       Date:  2013-03-27       Impact factor: 10.422

Review 9.  The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).

Authors:  Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2012-10-10       Impact factor: 21.566

10.  The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy.

Authors:  Luke A Massey; Hans R Jäger; Dominic C Paviour; Sean S O'Sullivan; Helen Ling; David R Williams; Constantinos Kallis; Janice Holton; Tamas Revesz; David J Burn; Tarek Yousry; Andrew J Lees; Nick C Fox; Caroline Micallef
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.